Illumina (ILMN)
(Delayed Data from NSDQ)
$121.05 USD
-1.82 (-1.48%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $120.75 -0.30 (-0.25%) 7:14 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
ILMN 121.05 -1.82(-1.48%)
Will ILMN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ILMN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ILMN
Illumina (ILMN) Expected to Beat Earnings Estimates: Should You Buy?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
ILMN: What are Zacks experts saying now?
Zacks Private Portfolio Services
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Other News for ILMN
Baron Focused Growth Fund Q1 2024 Shareholder Letter
Top high growth investment ratio stocks from each sector - GS
Engineering a Cool Career in Biotech - and Volunteering Along the Way
Evidence Supports Sequencing As First-Line Rare Disease Diagnostic
Illumina Inc. stock underperforms Tuesday when compared to competitors